Adjuvant Chemotherapy Not Recommended for Recurrent ER-Positive Breast Cancer


It was previously unknown whether patients with ER-positive disease would benefit from adjuvant chemotherapy.

Adjuvant chemotherapy does not reduce the number of disease-free survival events among patients with ER-positive breast cancer after isolated locoregional recurrence (ILRR), according to a study published in the Journal of Clinical Oncology.1

ILRR occurs at a relatively low rate but is strongly associated with mortality. The randomized phase 3 CALOR trial (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer; Identifier: NCT00074152) showed that patients with ER-negative disease may benefit from adjuvant chemotherapy after ILRR. It was unknown, however, whether patients with ER-positive disease would benefit from this strategy.

For the present report, researchers published the 9-month follow-up data from CALOR. Patients were stratified by ER status: of 58 patients with ER-negative disease, 29 were assigned each to chemotherapy and to no chemotherapy; of 104 patients with ER-positive disease, 56 were assigned to chemotherapy and 48 to no chemotherapy.

Patients in the ER-negative cohort had a median time to ILRR from primary cancer of 3.6 years. Patients in the ER-positive cohort, however, had a median time to ILRR of 6.8 years. All but 6% of patients in the ER-positive cohort previously received endocrine therapy.

Disease-free survival (DFS) events occurred at the highest rate among patients with ER-negative disease who did not receive chemotherapy (19 events, 66%), and at the lowest rate among those with ER-negative disease who received chemotherapy (8 events, 28%).

Chemotherapy did not, however, reduce the likelihood of a DFS event among patients with ER-positive disease (22 events, 39% vs 18 events with no chemotherapy, 38%). In the ER-positive cohort, the 10-year DFS rates were 50% with chemotherapy and 59% without.

The 10-year overall survival rate was improved in ER-negative patients who received chemotherapy (73% vs 53% without; hazard ratio, 0.48). The 10-year overall survival rates in the ER-positive group were 76% with chemotherapy vs 66% without (hazard ratio, 0.70).

The authors concluded that “[chemotherapy] offers the best prospect of prolonged DFS in patients with ER-negative first ILRR, whereas adding CT to endocrine therapy seems to offer no benefit to patients with ER-positive ILRR.”


  1. Wapnir IL, Price KN, Anderson SJ, et al. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial. J Clin Oncol. 2018 Feb 14. doi: 10.1200/JCO.2017.76.5719 [Epub ahead of print]

Source link

Products You May Like

Articles You May Like

Hospital Patients with Dementia Twice as Likely to Return Within 30 Days
Let This Silly Online Tool Plan Your Next Home Workout For You
Fibrocystic breast changes: Linked to breast cancer?
A tapering silicon hole could lead to better drug testing — ScienceDaily
Brain aging may begin earlier than expected — ScienceDaily

Leave a Reply

Your email address will not be published. Required fields are marked *